Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.51 |
| ▸ | ITGAL | P20701 | 3/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600490 | 1.00 | MDM4 (0.56) | MDM4TP53ITGB2ICAM1ITGAL | |
| SCHEMBL17269327 | 1.00 | MDM4 (0.56) | MDM4TP53ITGB2ICAM1ITGAL | |
| SCHEMBL28015870 | 1.00 | MDM4 (0.56) | MDM4TP53ITGB2ICAM1ITGAL | |
| SCHEMBL15164253 | 0.88 | MDM4 (0.48) | MDM4TP53MMEECE1MDM2 | |
| SCHEMBL27890071 | 0.88 | MDM4 (0.49) | MDM4TP53MMEECE1MDM2 | |
| SCHEMBL20106639 | 0.87 | MDM4 (0.47) | MDM4TP53CASP3 | |
| SCHEMBL17269328 | 0.82 | MDM4 (0.47) | MDM4TP53MDM2 | |
| SCHEMBL22444779 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3 | |
| SCHEMBL27041536 | 0.82 | MDM4 (0.56) | MDM4TP53MDM2CASP3 | |
| SCHEMBL118169 | 0.81 | MDM4 (0.59) | MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| CN-116059390-A | Prodrugs of cytotoxic actives with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | MDM4 2123/4885TP53 85/4885ITGB2 2388/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | MDM4 2123/4885TP53 85/4885ITGB2 2388/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | MDM4 2123/4885TP53 85/4885ITGB2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.